Using a convergent synthetic route to enable multiple points of diversity, a series of glucocorticoid receptor modulators (GRM) were profiled for potency, selectivity, and drug-like properties . Despite covering a large range of diversity, profiling the nonconjugated small molecule was suboptimal and they were conjugated to a mouse antitumor necrosis factor (TNF) antibody using the MP-Ala-Ala linker. Screening of the resulting antibody drug conjugates (ADCs) provided a better assessment of efficacy and physical properties, reinforcing the need to conduct structure-activity relationship studies on the complete ADC. DAR4 ADCs were screened in an acute mouse contact hypersensitivity model measuring biomarkers to ensure a sufficient therapeutic window. In a chronic mouse arthritis model, mouse anti-TNF GRM ADCs were efficacious after a single dose of 10 mg/kg i.p. for over 30 days. Data on the unconjugated payloads and mouse surrogate anti-TNF ADCs identified payload which was conjugated to a human anti-TNF antibody and advanced to the clinic as ABBV-3373.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.2c01579DOI Listing

Publication Analysis

Top Keywords

glucocorticoid receptor
8
antibody drug
8
mouse
5
discovery abbv-3373
4
anti-tnf
4
abbv-3373 anti-tnf
4
anti-tnf glucocorticoid
4
receptor modulator
4
modulator immunology
4
antibody
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!